Login to Your Account



Clinic Roundup


Wednesday, February 6, 2013

• Synageva BioPharma Corp., of Lexington, Mass., said a 12-week Phase I/II extension study data published in Hepatology showed that for seven patients with lysosomal acid lipase deficiency who completed dosing with sebelipase alfa, mean percent decreases for ALT and AST from both the initial baseline to week 12 were 52 percent and 36 percent, respectively (p < 0.05 for both).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription